496.60
-0.32%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.
View Swedish Orphan Biovitrum AB (publ) on TradingView ↗- Market value
- SEK 173.14bn
- Last close × shares
- Volume
- 519.3k
- Shares, 9 Nov 2026
- Price to earnings
- 353.5
About Swedish Orphan Biovitrum AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker SOBI.ST. It has been listed since 15 September 2006. In the fiscal year to 31 December 2025, it reported revenue of SEK 28.24bn and net income of SEK 478.0m. At that date it held total assets of SEK 67.43bn and shareholders' equity of SEK 37.72bn.
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The company is headquartered in Solna, Stockholm. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Latest on Swedish Orphan Biovitrum AB (publ)
Our reporting
- Swedish Orphan Biovitrum AB (publ) down 3.30% on Tuesday
- Swedish Orphan Biovitrum AB (publ) up 2.05% on Thursday
- Swedish Orphan Biovitrum AB (publ) up 3.06% on Wednesday
- Swedish Orphan Biovitrum AB (publ) up 2.24% on Wednesday
- Swedish Orphan Biovitrum AB (publ) up 2.15% on Tuesday
- Swedish Orphan Biovitrum AB (publ) up 2.39% on Wednesday
Next results
Due on 4 Feb 2027. Analysts expect earnings of 6.63 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Swedish Orphan Biovitrum AB (publ)'s ticker?
Swedish Orphan Biovitrum AB (publ) trades as SOBI.ST on Nasdaq Stockholm, under ISIN SE0000872095.
What was Swedish Orphan Biovitrum AB (publ)'s last closing price?
496.60 on 9 Nov 2026. The figure is in SEK and is never converted.
When does Swedish Orphan Biovitrum AB (publ) next report results?
Results are expected on 4 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- Our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.